-
1.发明申请CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERS 审中-公开CARBOSTYRIL衍生物和用于治疗疾病的MOOD STABILIZERS公开(公告)号：US20160030423A1
公开(公告)日：2016-02-04
申请号：US14795963
申请日：2015-07-10
发明人： Tetsuro Kikuchi , Taro Iwamoto , Tsuyoshi Hirose
IPC分类号： A61K31/496 , A61K31/19 , A61K31/55 , A61K31/5513 , A61K31/53 , A61K31/357 , A61K31/195 , A61K31/4015 , A61K33/00 , A61K31/423
CPC分类号： A61K31/496 , A61K31/19 , A61K31/195 , A61K31/357 , A61K31/4015 , A61K31/423 , A61K31/425 , A61K31/4704 , A61K31/497 , A61K31/53 , A61K31/55 , A61K31/5513 , A61K31/7008 , A61K33/00 , A61K33/14 , A61K45/06 , A61K2300/00
摘要： The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
摘要翻译： 本发明的药物组合物包含作为多巴胺 - 血清素系统稳定剂的喹诺酮衍生物和药学上可接受的载体中的情绪稳定剂。 喹诺酮类衍生物可以是阿立哌唑或其代谢物。 情绪稳定剂可以包括但不限于锂，丙戊酸，二丙酸钠，卡马西平，奥卡马沙平，唑尼沙胺，拉莫司定，托吡酯，加巴喷丁，左乙拉西坦或氯硝西泮。 这些组合物用于治疗情绪障碍的患者，特别是伴有或没有精神病特征，躁狂或混合发作的双相情感障碍。 提供了用于将单独施用喹诺酮衍生物和情绪稳定剂给患有情绪障碍的患者的方法。
-
2.发明申请公开(公告)号：US20170258788A1
公开(公告)日：2017-09-14
申请号：US15604720
申请日：2017-05-25
发明人： Tetsuro Kikuchi , Taro Iwamoto , Tsuyoshi Hirose
IPC分类号： A61K31/496 , A61K31/138 , A61K31/165 , A61K31/343 , A61K31/137 , A61K31/4525 , A61K31/15 , A61K31/135 , A61K31/381
CPC分类号： A61K31/496 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/15 , A61K31/165 , A61K31/343 , A61K31/381 , A61K31/4525 , A61P25/18 , A61P25/24 , A61P25/28 , A61K2300/00
摘要： The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
-
3.发明申请CARBOSTYRIL DERIVATIVES AND SEROTONIN REUPTAKE INHIBITORS FOR TREATMENT OF MOOD DISORDERS 审中-公开CARBOSTYRIL衍生物和用于治疗遗传疾病的丝氨酸蛋白酶抑制剂公开(公告)号：US20160310489A1
公开(公告)日：2016-10-27
申请号：US15176464
申请日：2016-06-08
发明人： Tetsuro Kikuchi , Taro Iwamoto , Tsuyoshi Hirose
IPC分类号： A61K31/496 , A61K31/138 , A61K31/381 , A61K31/135 , A61K31/165 , A61K31/15 , A61K31/4525 , A61K31/343 , A61K31/137
CPC分类号： A61K31/496 , A61K31/135 , A61K31/137 , A61K31/138 , A61K31/15 , A61K31/165 , A61K31/343 , A61K31/381 , A61K31/4525 , A61K2300/00
摘要： The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
摘要翻译： 本发明的药物组合物包含（1）喹诺酮衍生物和（2）可药用载体中的5-羟色胺再摄取抑制剂。 喹诺酮类衍生物可以是阿立哌唑或其代谢物，其是多巴胺5-羟色胺系统稳定剂。 5-羟色胺再摄取抑制剂可以是氟西汀，度洛西汀，文拉法辛，米那普仑，西酞普兰，氟伏沙明，帕罗西汀，舍曲林或依他普仑。 本发明的药物组合物可用于治疗情绪障碍，特别是抑郁症或重度抑郁症的患者。
-
公开(公告)号：US20200093823A1
公开(公告)日：2020-03-26
申请号：US16695777
申请日：2019-11-26
IPC分类号： A61K31/496 , A61K45/06
摘要： The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
-
公开(公告)号：US20210308126A1
公开(公告)日：2021-10-07
申请号：US16949571
申请日：2020-11-04
发明人： Tetsuro Kikuchi , Taro Iwamoto , Tsuyoshi Hirose
IPC分类号： A61K31/496 , A61K31/19 , A61K31/195 , A61K31/425 , A61K31/4704 , A61K31/497 , A61K31/55 , A61K31/7008 , A61K33/00 , A61K33/14 , A61K45/06 , A61K31/357 , A61K31/4015 , A61K31/423 , A61K31/53 , A61K31/5513
摘要： The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbemazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, manta or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
-
6.发明申请公开(公告)号：US20200289501A1
公开(公告)日：2020-09-17
申请号：US16664984
申请日：2019-10-28
发明人： Tetsuro Kikuchi , Taro Iwamoto , Tsuyoshi Hirose
IPC分类号： A61K31/496 , A61K31/135 , A61K31/15 , A61K31/165 , A61K31/343 , A61K31/381 , A61K31/4525 , A61K31/137 , A61K31/138 , A61P25/28 , A61P25/18 , A61P25/24
摘要： The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
-
7.发明申请公开(公告)号：US20190151308A1
公开(公告)日：2019-05-23
申请号：US16242315
申请日：2019-01-08
发明人： Tetsuro Kikuchi , Taro Iwamoto , Tsuyoshi Hirose
IPC分类号： A61K31/496 , A61K31/343 , A61P25/18 , A61P25/24 , A61P25/28
摘要： The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
-
公开(公告)号：US20170224681A1
公开(公告)日：2017-08-10
申请号：US15494877
申请日：2017-04-24
IPC分类号： A61K31/496
CPC分类号： A61K31/496 , A61K31/4704 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1) wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
-
公开(公告)号：US09006248B2
公开(公告)日：2015-04-14
申请号：US13932385
申请日：2013-07-01
IPC分类号： A61K31/497 , C07D401/00 , A61K31/496 , A61K45/06
CPC分类号： A61K31/496 , A61K31/4704 , A61K45/06 , A61K2300/00
摘要： The present invention relates to a method of treating a patient suffering from a disorder of the central nervous system associated with 5-HT1A receptor subtype, comprising as an active ingredient a carbostyril derivative or a salt thereof represented by the formula (1): wherein the carbon-carbon bond between 3- and 4-positions in the carbostyril skeleton is a single or a double bond.
摘要翻译： 本发明涉及一种治疗患有与5-HT 1A受体亚型相关的中枢神经系统紊乱的患者的方法，其包含由式（1）表示的喹诺酮衍生物或其盐作为活性成分：其中， 喹诺酮骨架中3-和4-位之间的碳 - 碳键是单键或双键。
-
公开(公告)号：US20240024310A1
公开(公告)日：2024-01-25
申请号：US18176533
申请日：2023-03-01
发明人： Tetsuro Kikuchi , Taro Iwamoto , Tsuyoshi Hirose
IPC分类号： A61K31/496 , A61K31/19 , A61K31/195 , A61K31/425 , A61K31/4704 , A61K31/497 , A61K31/55 , A61K31/7008 , A61K33/00 , A61K33/14 , A61K45/06 , A61K31/357 , A61K31/4015 , A61K31/423 , A61K31/53 , A61K31/5513
CPC分类号： A61K31/496 , A61K31/19 , A61K31/195 , A61K31/425 , A61K31/4704 , A61K31/497 , A61K31/55 , A61K31/7008 , A61K33/00 , A61K33/14 , A61K45/06 , A61K31/357 , A61K31/4015 , A61K31/423 , A61K31/53 , A61K31/5513
摘要： The pharmaceutical composition of the present invention comprises a carbostyril derivative which is a dopamine-serotonin system stabilizer and a mood stabilizer in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof. The mood stabilizer may include but is not limited to lithium, valproic acid, divalproex sodium, carbamazapine, oxcarbamazapine, zonisamide, lamotragine, topiramate, gabapentin, levetiracetam or clonazepam. These compositions are used to treat patients with mood disorders, particularly bipolar disorder with or without psychotic features, mania or mixed episodes. Methods are provided for separate administration of a carbostyril derivative and a mood stabilizer to a patient with a mood disorder.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.026 秒)
